MDM2 and neutropenia: Of the 4 patients with BTC in the combination trial who responded, 1 notable response occurred in a patient with MDM2-amplified GBC with a partial response, with a maximum tumor shrinkage of 50% observed.73 The most common any-grade treatment-related AEs were nausea (68% for monotherapy, 70% for combination therapy), fatigue (54% for monotherapy, 39% for combination therapy), and neutropenia (52% for monotherapy, 34% for combination therapy).